Questioning the quality of clinical data in economic analyses Newsletter Article 16 February 2013 Pages: 2 - 2
Is there a need for pharmacoeconomic evaluation? Nicholas Wells Newsletter Article 16 February 2013 Pages: 3 - 4
Debating the importance of newer vs older antidepressants Newsletter Article 16 February 2013 Pages: 4 - 4
Timely communication needed in therapeutic substitution Newsletter Article 16 February 2013 Pages: 5 - 5
Cost awareness does not necessarily mean cost savings Newsletter Article 16 February 2013 Pages: 5 - 5
‘Best Practice Guidelines’ reduce MRSA-associated costs Newsletter Article 16 February 2013 Pages: 6 - 6
Cost minimisation strategies targeted at anaesthetics Newsletter Article 16 February 2013 Pages: 6 - 6
The economic impact of HIV infection and tuberculosis Newsletter Article 16 February 2013 Pages: 7 - 7
NSAID prescribing - in need of treatment? Tracey LangsdaleRosie Stather Newsletter Article 16 February 2013 Pages: 8 - 9
Ribosomal vaccine promising for ear/nose/throat infections Newsletter Article 16 February 2013 Pages: 9 - 9
Droperidol comes out on top for postop nausea/vomiting Newsletter Article 16 February 2013 Pages: 10 - 10
Substantial costs associated with inappropriate cefotaxime prescribing Newsletter Article 16 February 2013 Pages: 11 - 11
Propranolol prophylaxis favourable in variceal bleeding Newsletter Article 16 February 2013 Pages: 11 - 11
Surgery is treatment of choice for acute limb ischaemia Newsletter Article 16 February 2013 Pages: 12 - 12
Helicobacter pylori eradication improves patient QOL Newsletter Article 16 February 2013 Pages: 13 - 13
Rationale for deleting oral ketorolac from a drug formulary Newsletter Article 16 February 2013 Pages: 14 - 14
Increasing quality of care essential to Canada’s healthcare reform Newsletter Article 16 February 2013 Pages: 15 - 15